No Data
Transcode Therapeutics Reports Increased Losses Amid Funding Challenges
Transcode Therapeutics | 10-Q: Q3 2024 Earnings Report
TransCode Therapeutics Urges Shareholders To Approve Potential Reverse Stock Split To Maintain Nasdaq Listing Amidst Capital Raising Needs; Vote Scheduled For November 22
TransCode Therapeutics Open Letter to Shareholders
Express News | Transcode Therapeutics Announces Nasdaq Extension to Regain Compliance
H.C. Wainwright Maintains Transcode Therapeutics(RNAZ.US) With Buy Rating, Maintains Target Price $3
No Data
No Data